Prdm12 Directs Nociceptive Sensory Neuron Development by Regulating the Expression of the NGF Receptor TrkA.


Journal

Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691

Informations de publication

Date de publication:
26 03 2019
Historique:
received: 15 10 2018
revised: 21 01 2019
accepted: 25 02 2019
entrez: 28 3 2019
pubmed: 28 3 2019
medline: 21 5 2020
Statut: ppublish

Résumé

In humans, many cases of congenital insensitivity to pain (CIP) are caused by mutations of components of the NGF/TrkA signaling pathway, which is required for survival and specification of nociceptors and plays a major role in pain processing. Mutations in PRDM12 have been identified in CIP patients that indicate a putative role for this transcriptional regulator in pain sensing. Here, we show that Prdm12 expression is restricted to developing and adult nociceptors and that its genetic ablation compromises their viability and maturation. Mechanistically, we find that Prdm12 is required for the initiation and maintenance of the expression of TrkA by acting as a modulator of Neurogenin1/2 transcription factor activity, in frogs, mice, and humans. Altogether, our results identify Prdm12 as an evolutionarily conserved key regulator of nociceptor specification and as an actionable target for new pain therapeutics.

Identifiants

pubmed: 30917309
pii: S2211-1247(19)30283-9
doi: 10.1016/j.celrep.2019.02.097
pii:
doi:

Substances chimiques

Basic Helix-Loop-Helix Transcription Factors 0
Carrier Proteins 0
Nerve Tissue Proteins 0
Neurog2 protein, mouse 0
Prdm12 protein, mouse 0
Neurog1 protein, mouse 182238-50-2
Tretinoin 5688UTC01R
Receptor, trkA EC 2.7.10.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3522-3536.e5

Subventions

Organisme : Medical Research Council
ID : MR/R006237/1
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom

Informations de copyright

Copyright © 2019 The Author(s). Published by Elsevier Inc. All rights reserved.

Auteurs

Simon Desiderio (S)

ULB Neuroscience Institute (UNI), Université Libre de Bruxelles (ULB), 6041 Gosselies, Belgium.

Simon Vermeiren (S)

ULB Neuroscience Institute (UNI), Université Libre de Bruxelles (ULB), 6041 Gosselies, Belgium.

Claude Van Campenhout (C)

ULB Neuroscience Institute (UNI), Université Libre de Bruxelles (ULB), 6041 Gosselies, Belgium.

Sadia Kricha (S)

ULB Neuroscience Institute (UNI), Université Libre de Bruxelles (ULB), 6041 Gosselies, Belgium.

Elisa Malki (E)

ULB Neuroscience Institute (UNI), Université Libre de Bruxelles (ULB), 6041 Gosselies, Belgium; KU Leuven, Interdepartmental Stem Cell Institute, Department of Development and Regeneration, Stem Cell Biology and Embryology, 3000 Leuven, Belgium.

Sven Richts (S)

Institute of Developmental Biochemistry, Center for Nanoscale Microscopy and Molecular Physiology of the Brain (CNMPB), University of Goettingen, 37077 Goettingen, Germany.

Emily V Fletcher (EV)

Cambridge Institute for Medical Research, University of Cambridge, CB2 0QQ Cambridge, UK.

Thomas Vanwelden (T)

KU Leuven, Interdepartmental Stem Cell Institute, Department of Development and Regeneration, Stem Cell Biology and Embryology, 3000 Leuven, Belgium.

Bela Z Schmidt (BZ)

KU Leuven, Interdepartmental Stem Cell Institute, Department of Development and Regeneration, Stem Cell Biology and Embryology, 3000 Leuven, Belgium.

Kristine A Henningfeld (KA)

Institute of Developmental Biochemistry, Center for Nanoscale Microscopy and Molecular Physiology of the Brain (CNMPB), University of Goettingen, 37077 Goettingen, Germany.

Tomas Pieler (T)

Institute of Developmental Biochemistry, Center for Nanoscale Microscopy and Molecular Physiology of the Brain (CNMPB), University of Goettingen, 37077 Goettingen, Germany.

C Geoffrey Woods (CG)

Cambridge Institute for Medical Research, University of Cambridge, CB2 0QQ Cambridge, UK; Department of Medical Genetics, University of Cambridge, CB2 0XY Cambridge, UK.

Vanja Nagy (V)

Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna Biocenter (VBC), 1030 Vienna, Austria; Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases, 1090 Vienna, Austria.

Catherine Verfaillie (C)

KU Leuven, Interdepartmental Stem Cell Institute, Department of Development and Regeneration, Stem Cell Biology and Embryology, 3000 Leuven, Belgium.

Eric J Bellefroid (EJ)

ULB Neuroscience Institute (UNI), Université Libre de Bruxelles (ULB), 6041 Gosselies, Belgium. Electronic address: ebellefr@ulb.ac.be.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH